Major salivary gland cancer
MONDO:0044743A primary or metastatic malignant neoplasm affecting the major salivary glands. Representative examples include carcinoma, lymphoma, and sarcoma.
Also known as: cancer of major salivary gland, malignant major salivary gland neoplasm, malignant major salivary gland tumor, malignant major salivary gland tumour, malignant neoplasm of major salivary gland, malignant neoplasm of the major salivary gland, malignant tumor of major salivary gland, malignant tumor of the major salivary gland
2969 clinical trials for this condition and its sub-types, 7 tagged with Major salivary gland cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Major salivary gland cancer
-
Parotid gland cancer 8 trials
1 sub-type
- Carcinoma of parotid gland 0 trials Sub-types →
-
Major salivary gland carcinoma 6 trials
6 sub-types
- Carcinoma of parotid gland 0 trials Sub-types →
- Major salivary gland adenoid cystic carcinoma 0 trials Sub-types →
- Major salivary gland carcinoma ex pleomorphic adenoma 0 trials Sub-types →
- Major salivary gland mucoepidermoid carcinoma 0 trials Sub-types →
- Sublingual gland carcinoma 0 trials Sub-types →
- Submandibular gland cancer 0 trials Sub-types →
-
Sublingual gland cancer 0 trials
1 sub-type
- Sublingual gland carcinoma 0 trials Sub-types →
Most studied deeper sub-types
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug shows promise against rare salivary gland cancer
Disease control OngoingThis study tests a new drug called APG-115, alone or with chemotherapy, in people with a certain type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the best dose with acceptable side effects. About 41 adults with…
Phase 1/2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control OngoingThis study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people with salivary gland cancer that has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. About 45 adults with advanced salivary…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC